---
title: "ZHEZHONG has repurchased a total of 5% of its shares, costing approximately 241 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238896673.md"
description: "According to the Zhitong Finance APP, ZHEZHONG announced that as of April 30, 2025, the company repurchased 22.1001 million shares through a dedicated securities repurchase account via centralized bidding, accounting for 5% of the company's total share capital, with a maximum transaction price of 11.5 yuan/share, a minimum transaction price of 9.44 yuan/share, and a total transaction amount of 241 million yuan"
datetime: "2025-05-06T11:12:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238896673.md)
  - [en](https://longbridge.com/en/news/238896673.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238896673.md)
generator: "portal-rs"
---

# ZHEZHONG has repurchased a total of 5% of its shares, costing approximately 241 million yuan

According to the Zhitong Finance APP, ZHEZHONG (002346.SZ) announced that as of April 30, 2025, the company will repurchase 22.1001 million shares through a dedicated securities repurchase account via centralized bidding, accounting for 5% of the company's total share capital, with a maximum transaction price of 11.5 yuan/share, a minimum transaction price of 9.44 yuan/share, and a total transaction amount of 241 million yuan

### Related Stocks

- [002346.CN](https://longbridge.com/en/quote/002346.CN.md)

## Related News & Research

- [Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41](https://longbridge.com/en/news/296530942.md)
- [Croatia orders detention of Ukrainian man wanted in Germany for Nord Stream blasts in 2022](https://longbridge.com/en/news/296522753.md)
- [08:56 ETMarco's Pizza Ranks as a Top Franchise Brand on 2026 QSR 50 List](https://longbridge.com/en/news/296495239.md)
- [12:15 ETGreenberg Traurig Earns Top Recognitions in The Best Lawyers in America®, Best Lawyers: Ones to Watch® in America 2027 Editions](https://longbridge.com/en/news/296637988.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**